Turning Point Therapeutics Updates Its IPO Filing – Will Raise Up to $152 Million

Turning Point Therapeutics, Inc., a clinical-stage precision oncology company designing and developing novel drugs to address treatment resistance, updated its S-1 Filing. The company is proposing a maximum offering of $152 million. Turning Point will offer 7,352,941 shares of common stock  and intends to trade under the symbol “TPTX”.